Publications by authors named "Yin-Shuang Wang"
Drug local delivery system that directly supply anti-cancer drugs to the tumor microenvironment (TME) results in excellent tumor control and minimizes side effects associated with the anti-cancer drugs. Immune checkpoint inhibitors (ICIs) have been the mainstay of cancer immunotherapy. However, the systemic administration of ICIs is accompanied by considerable immunotherapy-related toxicity.
View Article and Find Full Text PDFThe ongoing ENPOWER study exploring the efficacy and safety of the recombinant human endostatin (endostar) combined with programmed cell death 1 antibody sintilimab and chemotherapy showed encouraging efficacy and safety in advanced non-squamous non-small cell lung cancer. To evaluate the real-world efficacy and safety of endostar combined with immune checkpoint inhibitor and chemotherapy (EIC) for advanced non-squamous non-small cell lung cancer patients negative for actionable molecular biomarkers (NSCLCnm), patients with advanced NSCLCnm hospitalized to Zhejiang Provincial People's Hospital from January 2020 to December 2022 were screened for eligibility. The included patients were analyzed for the objective response rate (ORR) and disease control rate (DCR).
View Article and Find Full Text PDFArticle Synopsis
- Immune checkpoint inhibitors (ICIs) are important cancer treatments but can cause serious side effects known as immune-related adverse events (irAEs), including rare but severe cases like cytopenia.
- A 66-year-old man with metastatic lung adenocarcinoma experienced two episodes of pancytopenia after receiving ICIs, which required multiple treatments to manage.
- Despite eventually recovering from the second episode, he suffered a cerebral infarction, illustrating the critical need for early detection and treatment of hematological irAEs associated with ICIs.